诺和龙与阿托伐他汀联合治疗糖尿病肾病的临床疗效

发布时间：2017-12-27 13:28

本文关键词：诺和龙与阿托伐他汀联合治疗糖尿病肾病的临床疗效　出处：《中国老年学杂志》2016年11期 　论文类型：期刊论文

【摘要】：目的观察诺和龙与阿托伐他汀联合治疗糖尿病肾病(DN)的临床疗效。方法 100例DN患者随机分为对照组和观察组每组50例。对照组单纯给予诺和龙(1 mg/次,3次/d,三餐前20 min口服),观察组在对照组的基础上每晚8点左右给予口服阿托伐他汀15 mg,两组患者均给予严格的饮食运动治疗,疗程12 w。检测治疗前后两组患者的收缩压(SBP)、舒张压(DBP)、血肌酐(SCr)、空腹血糖(FBG)、餐后2 h血糖(2 h PBG)和糖化血红蛋白(Hb A1c)。结果与治疗前比较,治疗后两组DN患者的SBP、DBP、FPG、2 h PBG和Hb A1c水平均明显降低(P0.01),观察组较对照组显著降低(P0.05);对照组治疗前后SCr无显著差异,观察组治疗后Scr低于治疗前(P0.05)。结论诺和龙与阿托伐他汀联合治疗能更有效提高DN患者的治疗效果。
[Abstract]:Objective To observe the clinical effect of the combination of Nohe and atorvastatin in the treatment of diabetic nephropathy (DN). Methods 100 patients with DN were randomly divided into the control group and the observation group, with 50 cases in each group. The control group was given Nuo Helong only (1 mg/ times, 3 times /d, 20 min before meals). The observation group was given atorvastatin 15 mg every night at 8 o'clock on the basis of the control group. Two groups of patients were given strict diet and exercise therapy, the treatment course was 12 W. The systolic blood pressure (SBP), diastolic blood pressure (DBP), serum creatinine (SCr), fasting blood glucose (FBG), postprandial 2 h blood sugar (2 h PBG) and glycosylated hemoglobin (Hb A1c) were detected before and after treatment in two groups. Results compared with before treatment, the levels of SBP, DBP, FPG, 2 h PBG and Hb A1c in two groups of DN patients were significantly decreased after treatment (P0.01), the observation group was significantly lower than that in the control group (P0.05), the control group had no significant difference before and after treatment, and the observation group was lower than that before treatment. Conclusion the combination of nohellol and atorvastatin can improve the therapeutic effect of DN patients more effectively.
【作者单位】：北京市航空总医院内分泌科;吉林大学中日联谊医院病理科;
【基金】：北京市科技委员会资助项目(Z141100004914008)
【分类号】：R587.2;R692.9
【正文快照】： 糖尿病肾病(DN)糖尿病(DM)最严重的微血管并发症之一,是DM患者常见并发症及主要死亡原因〔1~3〕。以往的研究证明,诺和龙起效快、持久且能良好地控制血糖;阿托伐他汀能通过降低血脂及非依赖性降脂作用对DN起到保护作用〔4,5〕。本研究旨在观察诺和龙联合阿托伐他汀治疗DN患者

【相似文献】